Application Note: Endothelial Growth Factor-165 Recombinant Protein has been tested by SDS-PAGE and bioactivity and is suitable as a control for polyclonal or monoclonal anti-Endothelial Growth Factor-165 in immunological assays.
General Disclaimer Note: This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.
Other Performance Data: Endotoxin Level: Measured by kinetic LAL analysis and is typically ≤ 1 EU/μg protein. Biologic Activity: The activity is determined by the dose-dependent proliferation of HUVECs and is typically 1-6 ng/mL.
Physical State: Lyophilized
Purity and Specificity: Vascular Endothelial Growth Factor is produced with no animal-derived raw products, animal free equipment and animal free protocols. Purity was determined to be greater than 95% as determined by HPLC, analysis by UV-Spectroscopy at 280nm, and by reducing and non-reducing SDS-PAGE.
Background: Vascular Endothelial Growth Factor-A (VEGF-A) was originally isolated from tumor cells and is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability, VEGF-A may play a role in stimulating vasodilation via nitric oxide-dependent pathways. VEGF-A has several variants, VEGF-165 being the most abundant. Recombinant human VEGF 165 is a non-glycosylated homodimer, containing two 165 amino acids, with a total molecular weight of 38.2 kDa.
Low Endotoxin: Yes
Other: User Optimized